Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
INVESTING
Buy-the-Dip Candidates in the Stock Market: Tesla, Palantir
By Danny Peterson
Feb 17, 2021 8:13 AM EST
INVESTING
Buy-the-Dip Candidates in the Stock Market: Tesla, Palantir
By Danny Peterson
Feb 17, 2021 8:13 AM EST
PRESS RELEASES
Astellas And Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage Of PADCEV® (enfortumab Vedotin-ejfv) In Patients With Previously Treated Advanced Urothelial Cancer
By PR Newswire
Feb 12, 2021 2:15 PM EST
MARKETS
Bumble, Tilray, Disney, PepsiCo and Pinterest - 5 Things You Must Know Thursday
By Joseph Woelfel
Feb 11, 2021 6:29 AM EST
PRESS RELEASES
Seagen And Genmab Submit Tisotumab Vedotin Biologics License Application To The U.S. FDA For Patients With Recurrent Or Metastatic Cervical Cancer
By Business Wire
Feb 10, 2021 4:05 PM EST
PRESS RELEASES
Seagen To Host Conference Call And Webcast Discussion Of Fourth Quarter And Full Year 2020 Financial Results On February 11, 2021
By Business Wire
Jan 7, 2021 8:00 AM EST
INVESTING
5 Worst Stocks in the Nasdaq on Wednesday: Moderna Slides Again
By Fatma Khaled
Dec 30, 2020 6:15 PM EST
INVESTING
7 Worst Stocks in the Nasdaq on Wednesday: Zoom Sinks
By Fatma Khaled
Dec 23, 2020 4:44 PM EST
PRESS RELEASES
Seagen To Present At The J.P. Morgan Healthcare Conference
By Business Wire
Dec 16, 2020 8:00 AM EST
PRESS RELEASES
Alpine Immune Sciences Appoints Natasha Hernday To Board Of Directors
By Business Wire
Dec 11, 2020 8:00 AM EST
PRESS RELEASES
Seagen Announces Positive CHMP Opinion For TUKYSA® (tucatinib) For The Treatment Of Patients With Locally Advanced Or Metastatic HER2-Positive Breast Cancer
By Business Wire
Dec 11, 2020 7:23 AM EST
Video
Jim Cramer Picks Stocks You Should Buy, Sell or Hold
Nov 16, 2020 9:02 AM EST
PRESS RELEASES
Seagen To Host Virtual R&D Day On November 16, 2020
By Business Wire
Nov 2, 2020 8:00 AM EST
PRESS RELEASES
Seagen Announces Closing Of $1.0 Billion Stock Sale To Merck
By Business Wire
Oct 28, 2020 8:00 AM EDT
PRESS RELEASES
Seagen To Host Conference Call And Webcast Discussion Of Third Quarter 2020 Financial Results On October 29, 2020
By Business Wire
Oct 13, 2020 8:00 AM EDT
PRESS RELEASES
Seagen And Astellas Announce Positive Topline Results From Second Cohort Of Patients In Phase 2 Pivotal Trial Of PADCEV® (enfortumab Vedotin-ejfv) In Advanced Urothelial Cancer
By Business Wire
Oct 12, 2020 6:45 AM EDT
PRESS RELEASES
Astellas And Seagen Announce Positive Topline Results From Second Cohort Of Patients In Phase 2 Pivotal Trial Of PADCEV® (enfortumab Vedotin-ejfv) In Advanced Urothelial Cancer
By PR Newswire
Oct 12, 2020 6:45 AM EDT
PRESS RELEASES
Seattle Genetics And Genmab Present Data From Tisotumab Vedotin InnovaTV 204 Pivotal Trial In Recurrent Or Metastatic Cervical Cancer At ESMO Virtual Congress 2020
By Business Wire
Sep 21, 2020 10:20 AM EDT
INVESTING
5 Best Stocks in the Dow This Past Week
By Vidhi Choudhary
Sep 21, 2020 11:22 AM EDT
PRESS RELEASES
PADCEV® (enfortumab Vedotin-ejfv) (Photo: Business Wire)
By Business Wire
Sep 18, 2020 6:45 AM EDT
PRESS RELEASES
Astellas And Seattle Genetics Announce PADCEV® (enfortumab Vedotin-ejfv) Significantly Improved Overall Survival In Phase 3 Trial In Previously Treated Locally Advanced Or Metastatic Urothelial Cancer
By PR Newswire
Sep 18, 2020 6:45 AM EDT
JIM CRAMER
Still Undervalued: Cramer's 'Mad Money' Recap (Monday 9/14/20)
By Scott Rutt
Sep 14, 2020 9:00 PM EDT
INVESTING
Immunomedics, Scientific Games: 5 Top Gainers for Monday
By Rob Lenihan
Sep 14, 2020 4:21 PM EDT
Video
Jim Cramer: Nvidia's Going to Surpass Intel
Sep 14, 2020 11:30 AM EDT
INVESTING
Merck Takes Seattle Genetics Stake, Plans Cancer-Drug Venture
By Dan Weil
Sep 14, 2020 9:38 AM EDT
